###### Key questions

What is already known about this subject?
=========================================

-   Immunotherapy with checkpoint inhibitors has proven to yield remarkable responses in a variety of malignancies. It has been shown that in colorectal cancer (CRC), tumours with mismatch-repair-deficiency are especially susceptible to blockade with antibodies targeting PD-1 or PDL-1.

What does this study add?
=========================

-   To the best of our knowledge, this is the first report of a patient with a very large bulky tumour mass from her relapsing CRC that responded to PD-1-blockade with pembrolizumab after progressing under standard chemotherapy and bad performance status (ECOG 3) at initiation of therapy.

How might this impact on clinical practice?
===========================================

-   As there are novel therapeutic options now available for a subset of patients with mCRC , the microsatellite instability status should be assessed at the time of diagnosis. Immunotherapy with checkpoint inhibition might also be a therapeutic option in mCRC patients with bad performance status, not capable of receiving standard chemotherapy.

Background {#s1}
==========

Colorectal cancer (CRC) is the second most frequent cancer diagnosed in Europe with an incidence about 447 000 new cases per year. Approximately 25% of patients present with metastases at the time of initial diagnosis and nearly 50% of patients will develop metastases, contributing to the high mortality rates reported for CRC.[@R1] The CRC-5-years survival rate in Austria is about 65%.[@R2]

According to the ESMO Guidelines, the current standard for the treatment of mCRC is a cytotoxic doublet, consisting of a fluoropyrimidine plus oxaliplatin plus irinotecan, in combination with a monoclonal antibody against VEGF or EGFR (in RAS wild-type tumours).[@R3]

While in second line, the chemotherapy is switched and can be combined with monoclonal antibodies, in the salvage setting, regorafenib, a multikinase inhibitor, has shown efficacy in patients and is approved in Europe since 2013.[@R4] The drug combination of trifluridine/tipiracil has received a positive opinion by the European Medicines Agency and prolongs the survival of pretreated patients with mCRC as shown in a recent global phase III study and might be another therapeutic option for pretreated patients.[@R5]

With all these treatment options, the median overall survival of patients with mCRC or non-resectable disease is between 28.7[@R6] and 37.1 months[@R7] (FIRE 3, TRIBE).

Mismatch-repair-deficient CRC represents ∼10--20% of all patients with CRC and only 3--6% of patients with advanced CRC.[@R8] [@R9] In CRC, microsatellite instability (MSI), which refers to mutations in a tract of tandemly repeated DNA motifs (microsatellites), is typically caused by epigenetic silencing or mutation of DNA mismatch repair genes. The suggested approach to evaluate MSI is via PCR of five DNA markers or immunohistochemical analysis of DNA mismatch repair enzymes. Immunostaining of the mismatch repair enzymes MLH1, MSH2, MSH6 and PMS2 is equivalent in levels of sensitivity and specificity to MSI analysis via PCR.[@R10] In our centre, a two-step approach is performed. If the immunohistochemistry is negative for one of the above-mentioned mismatch repair enzymes, the suspected MSI is confirmed via PCR.

The microenvironment of microsatellite instable colon cancer displays high infiltration with activated CD8^+^ CTL as well as activated Th1 cells. It has been shown that MSI tumours counterbalance this active Th1/CTL microenvironment by expression of multiple immune checkpoints such as programmed death 1 (PD-1). The binding of PD-L1 or PD-L2 to PD-1 results in inhibition of T-cell immune functions and can constitute a form of immune escape mechanism.

In contrast to other tumours such as melanoma, renal or lung cancer, where PD-L1 is expressed by tumour cells, in MSI CRC PD-L1 is expressed predominantly by infiltrating myeloid cells.[@R11]

Advances in immunotherapy, especially blocking the negative feedback pathway of PD-1 with monoclonal antibodies, have shown remarkable clinical responses in patients with different types of cancers such as melanoma, non-small-cell-lung cancer, renal cell cancer, bladder cancer and Hodgkin\'s lymphoma.[@R12] In May 2015, Le *et al*[@R18] demonstrated the clinical activity of pembrolizumab, a humanised monoclonal anti PD-1 antibody of the IgG4 κ isotype blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, on treatment-refractory progressive mCRC with mismatch-repair deficiency. In this study, a small group of patients (n=10) with mismatch-repair-deficient CRC had a partial response in 40% and a stable disease at week 12 in 50%. In contrast, patients with mismatch-repair-proficient tumours did not respond to immunotherapy and pembrolizumab was almost ineffective. These stimulating results suggest a new therapeutic option in a carefully selected subset of patients with mCRC.

Case report {#s2}
===========

Here, we report the history of a 42-year-old woman, who was diagnosed with stage III KRAS mutant (G13D) CRC in 2013, when she underwent an emergency sigma resection due to perforation. She received adjuvant treatment with eight cycles of XELOX until January 2014. In December 2014, peritoneal metastases were detected and her overall physical status decreased steadily over time. Only five cycles of FOLFIRI were administered until September 2015. Suspected disease progression was confirmed when she was restaged, showing a large unresectable bulky peritoneal metastasis with about 11×11×14 cm holding in size (baseline size 11×11×14 cm, see [figures 1](#ESMOOPEN2016000084F1){ref-type="fig"} and [2](#ESMOOPEN2016000084F2){ref-type="fig"}). When she was referred to our department in September 2015, she was incapable to walk with a reduced performance status of ECOG 3. A molecular profile of the tumour revealed mismatch-repair deficiency of MLH1/PMS2 in the tumour DNA, but not in the germline DNA. In retrospect, the tumour showed a characteristic histological picture of a high number of tumour-infiltrating lymphocytes (see [figure 3](#ESMOOPEN2016000084F3){ref-type="fig"}). Hence, therapy with pembrolizumab (200 mg every 3 weeks) was initiated in the end of September 2015. After three cycles, a restaging was performed. No new metastases were diagnosed and compared to the last scan she had a stable disease mass. After these very promising results, the treatment with pembrolizumab for another three cycles were continued. At the end of December, a CT scan showed an impressive response with shrinkage of the peritoneal tumour mass to 25% of the original tumour volume (6.2×7.1×10.4 cm, see [figures 4](#ESMOOPEN2016000084F4){ref-type="fig"} and [5](#ESMOOPEN2016000084F5){ref-type="fig"}). Tumour markers CEA and CA 19-9 and LDH levels decreased to normal levels, haemoglobin level increased from 8 to 13 mg/dL and her overall clinical performance status increased from ECOG 3 to 1 within 3 months (see [figures 6](#ESMOOPEN2016000084F6){ref-type="fig"}[](#ESMOOPEN2016000084F7){ref-type="fig"}--[8](#ESMOOPEN2016000084F8){ref-type="fig"}). Restaging after 11 cycles of pembrolizumab showed further downsizing of the tumour mass (5.5×7.0×8.0 cm, see [figures 9](#ESMOOPEN2016000084F9){ref-type="fig"} and [10](#ESMOOPEN2016000084F10){ref-type="fig"}). The therapy with pembrolizumab is still ongoing.

![Axial baseline CT scan: large bulky peritoneal tumor mass with about 11×11×14 cm holding in size.](esmoopen2016000084f01){#ESMOOPEN2016000084F1}

![Coronal baseline CT scan: large bulky peritoneal tumor mass with about 11×11×14 cm holding in size.](esmoopen2016000084f02){#ESMOOPEN2016000084F2}

![Invasion front (pushing margin) of the patient\'s tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic for mismatch-repair-deficient (MMR) tumours.](esmoopen2016000084f03){#ESMOOPEN2016000084F3}

![Axial CT scan after six cycles of pembrolizumab shows a partial remission of the peritoneal tumour mass to 25% of the original tumour volume (6.2×7.1×10.4 cm).](esmoopen2016000084f04){#ESMOOPEN2016000084F4}

![Coronal CT scan after six cycles of pembrolizumab shows a partial remission of the peritoneal tumour mass to 25% of the original tumour volume (6.2×7.1×10.4 cm).](esmoopen2016000084f05){#ESMOOPEN2016000084F5}

![Axial CT scan after 11 cycles of pembrolizumab shows a further regression of the tumour mass to 5.5×7.0×8.0 cm.](esmoopen2016000084f06){#ESMOOPEN2016000084F6}

![Coronal CT scan after 11 cycles of pembrolizumab shows a further regression of the tumour mass to 5.5×7.0×8.0 cm.](esmoopen2016000084f07){#ESMOOPEN2016000084F7}

![Kinetics of serum tumor marker concentrations CEA and CA 19-9: from initiation of therapy in September 2015 to completion of 11 cycles pembrolizumab in late March 2016.](esmoopen2016000084f08){#ESMOOPEN2016000084F8}

![Lactate dehydrogenase (LDH) kinetics: from initiation of therapy in September 2015 to completion of 11 cycles pembrolizumab in late of March 2016.](esmoopen2016000084f09){#ESMOOPEN2016000084F9}

![Steady rise in hemoglobin concentration: from initiation of therapy in September 2015 to completion of 11 cycles pembrolizumab in late of March 2016.](esmoopen2016000084f10){#ESMOOPEN2016000084F10}

Discussion {#s3}
==========

While it has been proven that immunotherapy with checkpoint inhibitors may be a potent new therapeutic option in certain malignancies such as metastatic melanoma, so far in only a small sample size of patients with mCRC pembrolizumab had been tested. To the best of our knowledge, this is the first report of a sporadic MSI tumour, which responded after the failure of oxaliplatin, irinotecan and fluoropyrimidine, leading to a substantial response for at least 8 months and is ongoing. As demonstrated in previous publications and as we have also shown here, immunotherapy can yield remarkable responses in the subset of mismatch-repair-deficient colon cancer. For this reason, we emphasise the importance of testing for mismatch-repair status in metastatic disease.
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